Beyond the Genome: The Epitranscriptomic Revolution and the Quest for Precision Medicine

In the high-stakes world of precision medicine, the biological map is constantly being redrawn. For decades, the focus has remained firmly on the genome and, more recently, the transcriptome. Yet, despite monumental leaps in genomic sequencing and the advent of revolutionary therapies like checkpoint inhibitors and cell-based gene therapies, clinical outcomes remain stubbornly variable. A significant subset of patients continues to show limited or no response to these advanced interventions.

Gudrun Stengel, PhD, CEO of Alida Biosciences, argues that the missing link in our understanding of patient heterogeneity lies in a field often overlooked: epitranscriptomics. By studying the chemical modifications of RNA, Alida Biosciences is attempting to unlock the "missing layer" of gene regulation, providing a dynamic, high-resolution view of how cells respond to their environments and to life-saving drugs.

The Missing Link: Why Epitranscriptomics Matters

The central dogma of biology—DNA makes RNA, and RNA makes protein—has long been the framework for therapeutic development. However, Stengel points out that this linear view is incomplete. "We still have gaps in our understanding of how information flows from DNA to proteins and ultimately phenotype," she explains.

In the multiomics landscape, RNA modifications—the epitranscriptome—represent an essential, yet historically elusive, layer of the biological stack. While DNA methylation can take up to two weeks to reset, and RNA expression patterns can take a day, RNA modifications can alter a cell’s state in mere hours. This rapid responsiveness makes them a critical, yet previously unmeasured, indicator of cell health and drug susceptibility.

"RNA modifications don’t change the genetic code, but they change what RNA does," says Stengel. She highlights N6-methyladenosine (m6A) as the most pivotal modification. m6A acts as a cellular switch, marking transcripts for degradation or promoting the translation of proteins necessary for a cell’s transition to a new state. By regulating alternative splicing and translation efficiency, these modifications dictate protein diversity and cellular fate.

Chronology: From Concept to Commercialization

The journey of Alida Biosciences is a testament to the transition of epitranscriptomics from a niche academic pursuit to a clinical necessity.

• Five Years Ago: Driven by a desire to see a technology through from inception to full implementation, Dr. Stengel stepped away from a prominent career at industry giant Illumina. She recognized that while large corporations excel at scaling established technologies, the birth of entirely new platforms requires the agility and focused vision of a startup.
• Early Development: During the company’s infancy, epitranscriptomics was virtually unknown to the wider biotech community. Stengel’s core team worked in a lab environment, battling the technical difficulty of measuring RNA modifications, which are notoriously delicate and hard to capture accurately.
• 2025 – The Inflection Point: Alida Biosciences launched its proprietary EpiPlex™ platform. This was a watershed moment for the industry, as it provided the first commercial solution capable of analyzing sparse, highly degraded RNA—the type typically found in clinical samples like fresh-frozen tissues, formalin-fixed paraffin-embedded (FFPE) tissues, and liquid biopsies.
• Present Day: The company has transitioned from an R&D-heavy startup to a commercial entity, forming strategic partnerships with oncology leaders and integrating machine learning into its analysis pipelines.

The Technical Breakthrough: One-Pot Detection

One of the greatest barriers to the adoption of epitranscriptomics has been the reliance on nanopore-based direct RNA sequencing. While powerful, these methods traditionally required large quantities of pristine, full-length RNA, which is rarely available in clinical settings.

The EpiPlex platform bypassed this by offering "one-pot" detection. This approach allows for the simultaneous identification, localization, and quantification of three critical modifications—m6A, inosine, and pseudouridine—alongside gene expression data. By processing low-input and degraded samples, Alida Biosciences has effectively moved epitranscriptomics out of the specialized laboratory and into the realm of translational research.

Supporting Data and Clinical Utility

The potential applications for this technology are vast. In oncology, where patient stratification is the difference between a successful trial and a failed one, understanding the epitranscriptomic profile of a tumor could be transformative.

Alida Biosciences is currently collaborating with STORM Therapeutics to investigate the mechanism of action for a Phase II drug targeting Mettl3, the "writer" enzyme responsible for m6A modifications. This partnership serves as a proof-of-concept for how RNA modification profiling can be used to identify patients most likely to respond to targeted therapies.

Furthermore, the company is targeting the prediction of response to PD-L1 inhibitors. By measuring immune cell fitness through the lens of epitranscriptomics, clinicians may eventually be able to determine if a patient’s immune system is primed to react to immunotherapy before treatment even begins.

"m6A, the most common modification, plays a huge role in cell differentiation and cell fate," Stengel notes. By mapping these markers, researchers can gain insight into whether a cell is "stuck" in a disease-promoting state or if it is undergoing the necessary transitions to respond to treatment.

Official Perspectives: The Future of Biology

Dr. Stengel’s vision is centered on the integration of these data points into the broader AI-driven models of biology. She acknowledges that the industry is at a pivotal junction: "I think the next inflection point is when epitranscriptomics becomes part of mainstream multiomics."

As the company scales, its software, EpiScout®, is evolving to handle more complex datasets. By applying machine learning to the integration of RNA modifications and gene expression, Alida Biosciences aims to make their analysis output more interactive and clinically actionable.

"We are applying machine learning models to integrate the amount of information between RNA modifications and gene expression," says Stengel. This, she believes, will allow the research community to treat RNA modifications as a standard, mandatory layer in any comprehensive biological study.

Implications for the Future of Medicine

The implications of this work extend far beyond the laboratory. If epitranscriptomics becomes "clinically indispensable," as Stengel envisions, it will redefine how we classify diseases. Instead of defining a tumor solely by its genomic mutations, physicians may soon define it by its dynamic RNA state—a snapshot of the cell’s current behavior rather than its inherited potential.

For patients, this means fewer "trial and error" prescriptions. For the pharmaceutical industry, it means a higher probability of identifying the right patient population for a drug, potentially saving billions in R&D costs and, more importantly, saving lives.

As conferences across the globe begin to feature epitranscriptomics as a core topic rather than a side session, the message is clear: the field is maturing. While there is still work to be done in educating the wider medical community on the why behind these modifications, the momentum is undeniable.

"The real test will be demonstrating that this layer improves patient stratification, predicts treatment response, or identifies new therapeutic opportunities," Stengel concludes. "Once that happens, the field will move from being scientifically interesting to clinically indispensable."

With a robust technology platform in place and a clear commercial roadmap, Alida Biosciences stands at the forefront of this shift, ensuring that the "missing layer" of the biological stack finally takes its place in the standard toolkit of modern medicine. As AI continues to ingest and synthesize the vast quantities of data generated by the modern multiomics approach, the epitranscriptome will likely prove to be the key that unlocks a new, more precise era of therapeutic intervention.